07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Braasch preclinical data

In a mouse model of diet-induced obesity, Braasch's second-generation somatostatin vaccine significantly decreased weight gain vs. control mice. The amount of food intake was not affected by the vaccine. There also was a non-significant increase...
08:00 , Jan 11, 1999 |  BC Week In Review  |  Company News

Braasch Biotech Inc., Cobequid Life Sciences Inc. deal

Cobequid received co-exclusive rights worldwide to Braasch's patents covering DNA vaccines against rotaviruses in livestock and companion animals. Braasch Biotech Inc. , Garretson, S.D.   Cobequid Life Sciences Inc. (VSE:KQR), Richmond Hills, Ontario  ...